Innovative Therapeutics in Oncology and Neuroscience
Commercial Success with Science- and Portfolio-Driven Strategy
Expanded Patient Access to Five Commercial-Stage Products with Significant Revenue Growth
Once-daily oral
Zejula
niraparib
capsules 100 m
Supported by
NRDL
NRDL as the only
PARPI included for
first-line and
recurrent all-comer
settings in ovarian
cancer
Category 1
innovative drug
•
·
XOPTUNE
Only-in-class
GIO™
innovative treatment
option for GBM
No. 2 reimbursed in
supplemental
insurance plans
(SIP)1
QINLOCK
(ripretinib) 50 mg tablets
NRDL
Potential best-in-
class treatment for
advanced GIST
Recommended for
both 2L GIST and 4L
OGIST in China's 2023
CSCO Guidelines²
•
NUZYRAⓇ
(omadacycline
NRDL
Once-daily IV/PO
broad-spectrum
tetracycline with
favorable safety
and tolerability
profile
Category 1
innovative drug
•
VÝVGART
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial
NRDL
First approved
FcRn blocker in
the U.S., EU,
Japan, and China
⚫ Pipeline-in-a-
product: 15 in
development by
20253
Ⓡ
22
Abbreviations: Glioblastoma multiforme (GBM), gastrointestinal stromal tumors (GIST), intravenous (IV).
Notes: The trademarks and registered trademarks within are property of their respective owners. (1) Based on 4Q 2023 data, Meditrust Health disclosure; (2) Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of
Gastrointestinal Stromal Tumors 2023. In September 2023, QINLOCK was upgraded to the level I recommendation for second-line GIST patients harboring KIT exon 11 mutation with Category 1A evidence, based on the results from global Phase 3
INTRIGUE study and China bridging study; (3) indications under development by argenx, for which Zai Lab may consider for future development. argenx corporate presentation, November 2023.
zaiLabView entire presentation